March 24, 2026 | Blog

In today’s pharmaceutical manufacturing landscape, companies developing sterile injectables, biologics, cytotoxic drugs, or lyophilized products need speed, accuracy, and compliance at every step. When Quality Control (QC) is outsourced across multiple vendors, delays, fragmented documentation, and slow investigations often stand in the way of timely batch release.

 

BioTechnique solves this challenge by integrating QC directly into its full‑service CRDMO platform—connecting formulation, fill‑finish, lyophilization, warehousing, and QC within one facility to streamline decision-making and reduce risk.

 

The Power of Integrated QC

Integrated QC means analytical testing, microbiology, environmental monitoring (EM), lyophilization development, and electronic QMS systems all operate under one roof. This structure eliminates handoffs, shortens turnaround times, and keeps data consistent and inspection‑ready.

 

BioTechnique’s QC Program Includes:

• Analytical testing: HPLC/UPLC, FTIR, UV‑Vis, DSC, osmolality, Karl Fischer, TOC, and more.
• Microbiology: Endotoxin, bioburden, isolator‑based sterility testing, and rapid MALDI‑TOF identification.
• Environmental Monitoring: Viable and non‑viable air testing, surface/personnel monitoring, and cGMP‑aligned EM trending.
• Lyophilization support: Lab‑scale lyophilization, Freeze Drying Microscopy (FDM), Micropress, and Differential Scanning Calorimetry (DSC).
• Electronic QMS (ACE®): Real‑time documentation and audit‑ready reporting.

 

Where Siloed QC Falls Short

1. Slower timelines: External labs add sample transit and intake delays.
2. Documentation gaps: Multiple systems create version‑control risks.
3. Inefficient investigations: Integrated teams resolve issues faster.

 

A Better Model for Sterile Fill‑Finish Programs

BioTechnique’s sterile manufacturing capabilities—vials, syringes, cartridges, cytotoxic and high potent injectables, lyophilization, visual inspection, labeling, and packaging—are strengthened by integrated QC at every stage. With fewer handoffs, clients gain faster disposition, tighter sterility assurance, and stronger audit readiness.

 

About BioTechnique

BioTechnique, a division of PSC Biotech Corporation, is a full-service Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in cytotoxic and therapeutic sterile injectable fill-finish services. BioTechnique provides comprehensive support from investigation and clinical stages through commercialization, batch sizes both large and small.  

 

BioTechnique operates a state-of-the-art facility designed to handle a diverse range of pharmaceutical products, including cytotoxic and highly potent compounds, therapeutics, antibody-drug conjugates (ADCs), monoclonal antibodies, suspensions, and vaccines. Supported by an environmentally controlled warehouse and adaptable manufacturing systems, BioTechnique is committed to delivering high-quality fill-finish solutions.

 

Service Areas:

• Formulation development
• Aseptic fill‑finish
• Lyophilization
• QC testing & microbiology
• Environmental Monitoring
• R&D and QA support
• Warehousing & 3PL logistics
• Regulatory & project management

 

Explore more of BioTechnique’s capabilities at https://biotechnique.com/

Follow BioTechnique on LinkedIn for more updates and resources: https://www.linkedin.com/company/biotechnique/